Amneal Pharmaceuticals Inc banner
A

Amneal Pharmaceuticals Inc
F:2DT

Watchlist Manager
Amneal Pharmaceuticals Inc
F:2DT
Watchlist
Price: 10.6 EUR 0.95% Market Closed
Market Cap: €3.3B

P/FCFE

26.5
Current
440%
Cheaper
vs 3-y average of -7.8

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
26.5
=
Market Cap
€3.3B
/
Free Cash Flow to Equity
$145.1m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
26.5
=
Market Cap
€3.3B
/
Free Cash Flow to Equity
$145.1m

Valuation Scenarios

Amneal Pharmaceuticals Inc is trading above its industry average

If P/FCFE returns to its Industry Average (18.2), the stock would be worth €7.29 (31% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-31%
Maximum Upside
No Upside Scenarios
Average Downside
24%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 26.5 €10.6
0%
Industry Average 18.2 €7.29
-31%
Country Average 21.9 €8.76
-17%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
US
Amneal Pharmaceuticals Inc
F:2DT
3.3B EUR 26.5 53.3
US
Eli Lilly and Co
NYSE:LLY
883B USD 67.4 44.1
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 21 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 27.5 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 36.2 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 9.4 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 12.3 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD -766.6 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 24.3 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 24.3 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 19.3 16.6
P/E Multiple
Earnings Growth PEG
US
A
Amneal Pharmaceuticals Inc
F:2DT
Average P/E: 25.5
53.3
80%
0.7
US
Eli Lilly and Co
NYSE:LLY
44.1
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

In line with most companies in the United States of America
Percentile
58th
Based on 7 576 companies
58th percentile
26.5
Low
0 — 13.1
Typical Range
13.1 — 36.5
High
36.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.1
Median 21.9
70th Percentile 36.5
Max 3 188 432.5

Amneal Pharmaceuticals Inc
Glance View

Market Cap
3.3B EUR
Industry
Pharmaceuticals

Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale. Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.

2DT Intrinsic Value
15.6 EUR
Undervaluation 32%
Intrinsic Value
Price €10.6
A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett